Massey Quick Simon & CO. LLC acquired a new position in shares of VBI Vaccines Inc (NASDAQ:VBIV) during the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund acquired 22,547 shares of the biopharmaceutical company’s stock, valued at approximately $42,000.
Several other institutional investors have also recently added to or reduced their stakes in the company. Perceptive Advisors LLC increased its stake in shares of VBI Vaccines by 147.8% during the 4th quarter. Perceptive Advisors LLC now owns 23,951,556 shares of the biopharmaceutical company’s stock worth $38,322,000 after purchasing an additional 14,285,713 shares during the last quarter. Menora Mivtachim Holdings LTD. grew its stake in VBI Vaccines by 52.0% in the 4th quarter. Menora Mivtachim Holdings LTD. now owns 5,259,868 shares of the biopharmaceutical company’s stock valued at $8,416,000 after buying an additional 1,800,000 shares during the last quarter. General American Investors Co. Inc. grew its stake in VBI Vaccines by 104.1% in the 4th quarter. General American Investors Co. Inc. now owns 1,764,464 shares of the biopharmaceutical company’s stock valued at $2,823,000 after buying an additional 900,000 shares during the last quarter. Millennium Management LLC grew its stake in VBI Vaccines by 381.9% in the 4th quarter. Millennium Management LLC now owns 757,028 shares of the biopharmaceutical company’s stock valued at $1,211,000 after buying an additional 599,934 shares during the last quarter. Finally, Fosun International Ltd acquired a new position in VBI Vaccines in the 4th quarter valued at about $935,000. Institutional investors own 53.01% of the company’s stock.
Shares of VBIV opened at $2.08 on Wednesday. VBI Vaccines Inc has a 52 week low of $1.14 and a 52 week high of $3.95. The stock has a market capitalization of $206.07 million, a P/E ratio of -2.14 and a beta of 1.26. The company has a current ratio of 2.64, a quick ratio of 2.60 and a debt-to-equity ratio of 0.13.
VBI Vaccines (NASDAQ:VBIV) last announced its quarterly earnings results on Monday, February 25th. The biopharmaceutical company reported ($0.28) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.19) by ($0.09). VBI Vaccines had a negative net margin of 1,895.74% and a negative return on equity of 68.48%. Equities analysts expect that VBI Vaccines Inc will post -0.54 earnings per share for the current year.
A number of research analysts recently commented on VBIV shares. Oppenheimer started coverage on shares of VBI Vaccines in a research note on Wednesday, January 16th. They issued an “outperform” rating and a $9.00 price target on the stock. ValuEngine lowered shares of VBI Vaccines from a “buy” rating to a “hold” rating in a research note on Wednesday, January 2nd. Finally, Zacks Investment Research lowered shares of VBI Vaccines from a “buy” rating to a “hold” rating in a research note on Tuesday, January 22nd.
ILLEGAL ACTIVITY NOTICE: This piece of content was originally posted by Macon Daily and is the sole property of of Macon Daily. If you are reading this piece of content on another site, it was illegally stolen and reposted in violation of US & international copyright & trademark legislation. The original version of this piece of content can be viewed at https://macondaily.com/2019/04/17/massey-quick-simon-co-llc-takes-42000-position-in-vbi-vaccines-inc-vbiv.html.
About VBI Vaccines
VBI Vaccines Inc, a biopharmaceutical company, develops and sells vaccines to address unmet needs in infectious disease and immuno-oncology in Israel and internationally. The company offers Sci-B-Vac, a prophylactic hepatitis B vaccine for adults, children, and newborns; and eVLP, a vaccine platform for the design of enveloped virus-like particle vaccines that closely mimic the structure of the target virus.
Featured Story: What is Cost of Capital?
Want to see what other hedge funds are holding VBIV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for VBI Vaccines Inc (NASDAQ:VBIV).
Receive News & Ratings for VBI Vaccines Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for VBI Vaccines and related companies with MarketBeat.com's FREE daily email newsletter.